Very light in detail
Sydney, Australia, 2 May 2022: Imugene (ASX: IMU) today announced termination of its
supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ., USA.
Imugene is continuing with its clinical trial to evaluate the safety and efficacy with the use of
Imugene’s HER-Vaxx, a B-cell activating immunotherapy in patients with HER-2 positive
gastric cancer in combination with anti-PD-1 therapy.
Ann: Termination of Supply Agreement, page-4
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.5¢ |
Change
0.001(1.19%) |
Mkt cap ! $622.1M | |||
| Open | High | Low | Value | Volume |
| 8.3¢ | 8.6¢ | 8.2¢ | $1.062M | 12.66M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 495709 | 8.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.5¢ | 919740 | 6 |
View Market Depth
| Last trade - 16.10pm 02/05/2024 (20 minute delay) ? |
|
|||||
|
Last
8.4¢ |
Change
0.001 ( 0.84 %) |
||||
| Open | High | Low | Volume | ||
| 8.4¢ | 8.6¢ | 8.2¢ | 6843386 | ||
| Last updated 15.59pm 02/05/2024 ? | |||||
| IMU (ASX) Chart |